 Aldeyra Therapeutics Inc NASDAQ: ALDX achieved the primary endpoints in a crossover clinical trial of 0.25 reproxalap ophthalmic solution, an investigational new drug candidate for dry eye disease. Relative to the vehicle, a statistically significant reduction in ocular. 